IBDEI0H4 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8278,0)
 ;;=379.24^^52^580^105
 ;;^UTILITY(U,$J,358.3,8278,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8278,1,3,0)
 ;;=3^Vitreous Floaters
 ;;^UTILITY(U,$J,358.3,8278,1,4,0)
 ;;=4^379.24
 ;;^UTILITY(U,$J,358.3,8278,2)
 ;;=Vitreous Floaters^88242
 ;;^UTILITY(U,$J,358.3,8279,0)
 ;;=379.26^^52^580^107
 ;;^UTILITY(U,$J,358.3,8279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8279,1,3,0)
 ;;=3^Vitreous Prolapse
 ;;^UTILITY(U,$J,358.3,8279,1,4,0)
 ;;=4^379.26
 ;;^UTILITY(U,$J,358.3,8279,2)
 ;;=Vitreous Prolapse^269312
 ;;^UTILITY(U,$J,358.3,8280,0)
 ;;=379.23^^52^580^106
 ;;^UTILITY(U,$J,358.3,8280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8280,1,3,0)
 ;;=3^Vitreous Hemorrhage
 ;;^UTILITY(U,$J,358.3,8280,1,4,0)
 ;;=4^379.23
 ;;^UTILITY(U,$J,358.3,8280,2)
 ;;=Vitreous Hemorrhage^127096
 ;;^UTILITY(U,$J,358.3,8281,0)
 ;;=362.18^^52^580^89
 ;;^UTILITY(U,$J,358.3,8281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8281,1,3,0)
 ;;=3^Retinal Vasculitis
 ;;^UTILITY(U,$J,358.3,8281,1,4,0)
 ;;=4^362.18
 ;;^UTILITY(U,$J,358.3,8281,2)
 ;;=Retinal Vasculitis^264463
 ;;^UTILITY(U,$J,358.3,8282,0)
 ;;=360.21^^52^580^31
 ;;^UTILITY(U,$J,358.3,8282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8282,1,3,0)
 ;;=3^Degenerative Myopia
 ;;^UTILITY(U,$J,358.3,8282,1,4,0)
 ;;=4^360.21
 ;;^UTILITY(U,$J,358.3,8282,2)
 ;;=Degenerative Myopia^268553
 ;;^UTILITY(U,$J,358.3,8283,0)
 ;;=362.64^^52^580^80
 ;;^UTILITY(U,$J,358.3,8283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8283,1,3,0)
 ;;=3^Reticular Degeneration
 ;;^UTILITY(U,$J,358.3,8283,1,4,0)
 ;;=4^362.64
 ;;^UTILITY(U,$J,358.3,8283,2)
 ;;=Reticular Degeneration^268645
 ;;^UTILITY(U,$J,358.3,8284,0)
 ;;=362.61^^52^580^29
 ;;^UTILITY(U,$J,358.3,8284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8284,1,3,0)
 ;;=3^Degeneration, Paving Stone
 ;;^UTILITY(U,$J,358.3,8284,1,4,0)
 ;;=4^362.61
 ;;^UTILITY(U,$J,358.3,8284,2)
 ;;=Paving Stone Degeneration^268642
 ;;^UTILITY(U,$J,358.3,8285,0)
 ;;=362.42^^52^580^94
 ;;^UTILITY(U,$J,358.3,8285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8285,1,3,0)
 ;;=3^Rpe Detachment, Serous
 ;;^UTILITY(U,$J,358.3,8285,1,4,0)
 ;;=4^362.42
 ;;^UTILITY(U,$J,358.3,8285,2)
 ;;=Serous RPE Detachment^268633
 ;;^UTILITY(U,$J,358.3,8286,0)
 ;;=362.43^^52^580^93
 ;;^UTILITY(U,$J,358.3,8286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8286,1,3,0)
 ;;=3^Rpe Detachment, Hemorrhagic
 ;;^UTILITY(U,$J,358.3,8286,1,4,0)
 ;;=4^362.43
 ;;^UTILITY(U,$J,358.3,8286,2)
 ;;=Hemorrhagic RPE Detachment^268634
 ;;^UTILITY(U,$J,358.3,8287,0)
 ;;=250.00^^52^580^34
 ;;^UTILITY(U,$J,358.3,8287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8287,1,3,0)
 ;;=3^Dm Type II, No Retinopathy
 ;;^UTILITY(U,$J,358.3,8287,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,8287,2)
 ;;=DM Type II, No Retinopathy^33605
 ;;^UTILITY(U,$J,358.3,8288,0)
 ;;=250.01^^52^580^33
 ;;^UTILITY(U,$J,358.3,8288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8288,1,3,0)
 ;;=3^Dm Type I, No Retinopathy
 ;;^UTILITY(U,$J,358.3,8288,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,8288,2)
 ;;=DM Type I, No Retinopathy^33586
 ;;^UTILITY(U,$J,358.3,8289,0)
 ;;=250.50^^52^580^25
 ;;^UTILITY(U,$J,358.3,8289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8289,1,3,0)
 ;;=3^Csme In DM Type II
 ;;^UTILITY(U,$J,358.3,8289,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,8289,2)
 ;;=CSME in DM type II^267839^362.83
 ;;^UTILITY(U,$J,358.3,8290,0)
 ;;=250.51^^52^580^27
 ;;^UTILITY(U,$J,358.3,8290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8290,1,3,0)
 ;;=3^DM Type I w/ Ophtharlmic Manifestation
 ;;^UTILITY(U,$J,358.3,8290,1,4,0)
 ;;=4^250.51
